Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Regulatory & Legal

TITLE:

EMA: CHMP adopted a positive opinion for Prevymis (letermovir) film-coated tablets (240 mg and 480 mg) from Merck Sharp & Dohme Limited.

BRIEF:

EMA: CHMP adopted a positive opinion for Prevymis (letermovir) film-coated tablets (240 mg and 480 mg) from Merck Sharp & Dohme Limited. Prevymis is intended for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) (ATC code: J05AX18). The EC Decision will follow soon.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company